Align Technology stock trades below analyst targets as Q2 2026 growth slows

Align Technology Inc. (ISIN US0162551016) stock is trading in the mid-$160 range as of August 19, 2026, reflecting a modest gain for the year but sitting below where analysts see fair value for the clear-aligner specialist.

Recent coverage as of August 19, 2026, shows Align shares at $167.91, down 1.9% on the session, with the stock having started 2026 at $156.15 and gained 7.5% year to date. This quote overview sets a 1-year trading range between $122.00 and $200.43, indicating that the current level sits comfortably in the middle of the recent band.

Analyst data compiled over the last twelve months points to a consensus price target of $206.36 on Align Technology, indicating a forecasted upside of roughly 19% from a fair-value price of $173.33 quoted on August 19, 2026. The forecast overview shows twelve-month targets stretching from $150.00 on the low end to $240.00 on the high end, underlining a generally constructive but not euphoric stance among covering firms.

Q2 2026 results show slower but positive growth

Align Technology reported its latest quarterly figures for the second quarter of 2026, giving investors a current view of demand for its clear aligners and intraoral scanners.

Per an earnings summary dated August 19, 2026, Align posted Q2 2026 revenue of $1.06 billion, representing a 4.3% year-over-year increase from the prior-year quarter. The earnings snippet attributes this growth primarily to strong shipments of Clear Aligner products, highlighting that demand is still expanding even if growth has cooled from earlier periods.

The Q2 2026 comparison is notable: a revenue base of $1.06 billion growing 4.3% year over year suggests that incremental gains are coming from volume rather than pricing power alone, and that Align is navigating a more mature phase of category penetration. For investors, the slower growth rate compared with earlier double-digit periods makes margin management and cost discipline more important in assessing long-term value.

Management has also been working through specific headwinds in Q2 2026. The same earnings summary notes that the company is conducting a strategic review and adjusting guidance as it shifts customers to lower-cost scanner models, while absorbing a stated UK VAT liability of £37.5 million. The combination of product mix changes and tax-related costs means that revenue growth alone does not tell the full story of profitability for the quarter.

Analyst consensus and valuation context

Analysts currently describe the stock’s rating profile as moderately positive. The rating overview reports an average rating score of 2.67 on a scale where higher reflects more bullish views, built from one strong-buy rating, eight buy ratings, and six hold ratings, with no explicit sell recommendations in the latest tally.

On valuation, the consensus price target of $206.36 compared with a real-time fair-value quote of $173.33 on August 19, 2026, implies upside of 19.06%. The forecast page calculates this gap using price objectives issued over the last twelve months, suggesting that the market price in the $160s leaves room for repricing if the company can sustain revenue growth and address margin headwinds.

Viewed over a longer horizon, Align Technology shares have traded between $122.00 and $200.43 during the past year. An institutional-holdings update reiterates this 1-year low-high range and notes that the 50-day moving average stands at $175.77 while the 200-day moving average is $175.63, placing the current quote modestly below both trend lines.

For investors who track moving averages as a proxy for momentum, trading below both the 50-day and 200-day levels can signal a period of consolidation rather than aggressive trending, especially when the fundamental story shows slower single-digit growth rather than rapid expansion. The existing analyst targets imply that, from these levels, the stock would need to advance more than $30 per share to reach the average objective.

Institutional flows and market behavior

Recent filings highlight that institutional investors continue to adjust their exposure to Align Technology.

One filing alert dated August 19, 2026, reports that a featured advisory firm opened a position in Align shares valued at $1.13 million, with the trading summary stating that shares opened at $167.91 on that day and that the stock traded down 1.9% during the session. The position alert remarks that the stock was described as trading down 1.9%, matching the quoted price performance in the broader overview.

Another institutional holdings note released on August 19, 2026, cites a new investor adding Align Technology to its portfolio and comments that the shares were trading down 1.9% at $167.91 in that context. The holdings summary reinforces that institutional interest remains present even as day-to-day price action shows mild declines rather than sharp rallies.

The fact that new institutional positions are being initiated while the stock trades below its recent moving averages can be read as a vote of confidence in Align Technology’s long-term cash-generation potential. Yet, the size of these disclosed positions relative to the company’s multi-billion-dollar market capitalization suggests that investors are layering in exposure cautiously, rather than making outsized bets on near-term catalysts.

Product focus: Invisalign clear aligners

Align Technology’s flagship product line is Invisalign, a suite of clear aligner treatments designed to straighten teeth using custom-made, removable plastic trays instead of traditional metal braces.

The Q2 2026 earnings commentary describes Clear Aligner shipments as the primary driver of the quarter’s 4.3% year-over-year revenue growth, emphasizing that demand from general practitioners and orthodontists remains solid across key geographies. The Q2 2026 snippet reinforces that the clear-aligner segment still accounts for the bulk of Align’s top-line performance.

Invisalign treatments are built from digital scans of a patient’s mouth and rely on iterative sets of aligners that apply gentle pressure to move teeth into desired positions over time. The model depends not only on patient adoption but also on dentists’ and orthodontists’ willingness to invest in Align’s scanner hardware and treatment-planning software, which is why the noted shift toward lower-cost scanner models in Q2 2026 matters for overall economics.

From a business standpoint, every Invisalign case represents a combination of device revenue and associated digital services, creating a recurring relationship between Align Technology and dental practices. The 4.3% revenue increase in Q2 2026 suggests that the installed base of practitioners is still expanding or that existing customers are processing more cases, which matters for long-run growth even in the face of short-term pricing changes.

Stock price context and as-of data

For valuation and trading context, several real-time and closing-price data points frame where Align Technology stock stands as of mid-August 2026.

A closing-price summary dated August 18, 2026, lists Align shares at $167.91 at 4:00 p.m. Eastern, with extended trading showing $169.28 at 8:01 a.m. Eastern on the following session. The daily quote highlights that the -1.90% decline at the August 18 close contrasts with broader YTD gains of 7.5% from the $156.15 level recorded at the start of 2026.

Another intraday fair-value snapshot dated August 19, 2026, reports the price at $173.33 with a 3.23% move for the day, indicating that trading can be relatively volatile across sessions even when the one-year range spans from $122.00 to $200.43. The fair-value price estimate uses this $173.33 level as the baseline from which it calculates the 19.06% upside to the consensus target.

Separately, another quote feed as of August 14, 2026, shows Align Technology closing at $181.31 with a 2.90% gain on that session and an after-hours price of $180.00, down 0.72% later in the evening. The August 14, 2026 close illustrates that, within less than a week, the stock has traded a band from $163.03 on a later closing snapshot up to $181.31, underscoring active investor engagement around the name.

At a current level in the $160s to low $170s, and with a one-year high of $200.43, Align Technology shares would need to gain more than 17% to revisit that peak, using $167.91 as the reference price. That spread offers a concrete sense of upside potential relative to recent trading history, separate from the analyst target framework.

Business model and strategic considerations

Beyond the headline numbers, Align Technology’s Q2 2026 narrative reveals several strategic themes that matter for long-run investors evaluating the stock.

First, the company’s decision to adjust guidance while transitioning customers toward lower-cost scanner models suggests a deliberate effort to align pricing with market conditions and perhaps increase accessibility for a broader range of dental practices. While lower-priced hardware can compress average selling prices, it may also expand the installed base and drive more Invisalign case volume over time, supporting recurring revenue from aligner shipments and software services.

Second, the acknowledgment of a £37.5 million UK VAT liability in Q2 2026 points to non-operational headwinds that can affect reported earnings and cash flows. This liability, as referenced in the Q2 2026 summary, needs to be considered when comparing current profitability to prior periods that did not bear the same tax burden. The impact on margins can be material, especially in a quarter where top-line growth is in the mid-single-digit range.

Third, the global competitive landscape in dental devices and clear aligners features peers whose recent results show mid-to-high single-digit organic growth, as evidenced by another dental-sector update noting 8.5% organic revenue growth in the second quarter for a major implant and orthodontics player and 7.8% for the first half of the year. This peer report underscores that Align’s 4.3% revenue growth in Q2 2026 is lower than some competitors’ growth rates, making relative performance an important angle in valuation discussions.

When viewed against these sector benchmarks, Align Technology’s single-digit revenue expansion may still be acceptable given its larger scale and established market presence, but it also signals that the era of rapid, double-digit category growth may be behind it. Sustained investment in new product features, software integration and orthodontist education will likely be necessary to keep growth at or above sector averages.

Investor takeaway on Align Technology stock

For US retail investors, the current Align Technology story combines a solid but slower growth profile with ongoing strategic and regulatory adjustments.

Q2 2026 revenue of $1.06 billion with a 4.3% year-over-year increase confirms that demand for Invisalign and associated technologies remains positive, even as headwinds like the £37.5 million UK VAT liability weigh on profitability and guidance revisions. The stock’s one-year trading range from $122.00 to $200.43, and its mid-August pricing between the low $160s and low $170s, frame a risk-reward profile where shares are neither at distress levels nor at prior peaks.

Analyst consensus data pointing to an average price target of $206.36 and a moderate-buy rating indicates that professional coverage still sees upside if Align can execute on its strategic review, manage scanner mix shifts and navigate tax and regulatory issues. For investors, the key metrics to watch after Q2 2026 will be the pace of Clear Aligner case growth, scanner adoption trends, and any updates to guidance that clarify how management expects to balance growth and margins over the next several quarters.

As of the most recent completed trading session with a clearly stated close, Align Technology stock ended at $167.91 on August 18, 2026 on the Nasdaq, with associated data citing a 1.90% decline on the day and YTD gains of 7.5% from the start-of-year level at $156.15. The closing snapshot offers a concrete benchmark for investors evaluating entry and exit points in the context of the consensus price target and the recent one-year high.

Go deeper

Investors seeking more detail on Align Technology’s latest earnings, margin drivers and strategic review can find additional figures and commentary in the Q2 2026 earnings overview, as well as in the consensus analyst reports that underpin the current price targets and ratings.

Investor Relations

Further official information on Align Technology’s business, products and corporate governance is available via the company’s investor relations website, which hosts quarterly reports, presentations and regulatory filings that provide deeper visibility into operating metrics, geographic trends and long-term strategy.

Fact box

Company: Align Technology Inc.

ISIN: US0162551016

Ticker: ALGN

Exchange: Nasdaq

Price (as of August 18, 2026, 4:00 p.m. ET): $167.91 USD

Market cap: reference data sets Align Technology as a multi-billion-dollar healthcare equipment and supplies issuer, consistent with its Nasdaq listing and global clear-aligner presence.

Sector / Industry: Healthcare / Healthcare Equipment and Supplies

Index membership: widely followed US indices include broad-market benchmarks where Align’s healthcare equipment classification can feature via sector ETFs and specialized healthcare portfolios.